Net earnings per share for the last 12 months: Cara Therapeutics Inc. (CARA)

The failure of final tests undermined the market resilience of Cara Therapeutics, Inc. (CARA), causing the company's net income per share over 12 months—whose current chart on GURU.Markets contains -2.70 as the base parameter value—to trend downward. Growth potential is based on selective agonists against pruritus, however, geopolitical strife and sanctions are blocking international shipments of biomaterials.
Analytical breakdowns and data insights for company Cara Therapeutics Inc (CARA)

The performance of Cara Therapeutics, Inc. (CARA) is reflected in the company's specific annual income metric, which links pharmaceutical market specifics to profitability. This metric represents the net income distributed per common share over the last twelve months. The calculation excludes the impact of issuance volume, allowing for an assessment of real capital generation efficiency. For the issuer, this is a critical marker of stability against the backdrop of clinical trial costs. Growth in this indicator confirms the business's ability to overcome regulatory pricing pressure.